Status:
COMPLETED
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Lead Sponsor:
Pfizer
Conditions:
Kidney Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regi...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis
- Evidence of measurable disease
- Must have failed one prior systemic first-line regimen for metastatic renal cell cancer
Exclusion
- Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy
- Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug
Key Trial Info
Start Date :
September 3 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 25 2016
Estimated Enrollment :
723 Patients enrolled
Trial Details
Trial ID
NCT00678392
Start Date
September 3 2008
End Date
February 25 2016
Last Update
January 9 2019
Active Locations (294)
Enter a location and click search to find clinical trials sorted by distance.
1
East Valley Hematology and Oncology Medical Group
Burbank, California, United States, 91505
2
Maurice Berkowtiz, MD
Burbank, California, United States, 91505
3
Agajanian Institute of Oncology and Hematology
Downey, California, United States, 90241
4
Los Angeles Hematology/Oncology Medical Group
Glendale, California, United States, 91206